Clinical Trials on Progressive Familial Intrahepatic Cholestasis in Korea, Democratic People's Republic of

Total 13 results

Asan Medical Center

Completed

Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic Stents

Cholestasis, Extrahepatic

Korea, Republic of
Woo Hyun Paik

Terminated

The Effect of Aspirin on Patency of Metal Stent in Malignant Distal Bile Duct Obstruction

Biliary Stasis, Extrahepatic

Korea, Republic of
Asan Medical Center

Completed

EUS-guided Biliary Drainage Versus Percutanenous Transhepatic Biliary Darinage for Malignant Biliary Obstruction After Failed ERCP

Cholestasis, Extrahepatic

Korea, Republic of
Gangnam Severance Hospital

Recruiting

Clinical Validation of an Immunocytochemistry Method Using MARS1 (MARS1)

Bile Duct Obstruction, Extrahepatic

Korea, Republic of
Gangnam Severance Hospital
Korea Institute of Science and Technology

Completed

Development of a New Immunochemistry Method Using Antibodies of Proteins Related Bile Duct Cancer

Bile Duct Obstruction, Extrahepatic

Korea, Republic of
CymaBay Therapeutics, Inc.

Recruiting

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Hepatic Impairment | Compensated Cirrhosis | Primary Biliary Cholangitis

Korea, Republic of, United States, Spain, United Kingdom
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis (AFFIRM)

Primary Biliary Cholangitis

United States, Korea, Republic of, Turkey
Ipsen

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

Primary Biliary Cholangitis (PBC)

United States, Spain, France, Korea, Republic of, Italy, Czechia, Poland, Romania
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more

Clinical Trials on Progressive Familial Intrahepatic Cholestasis in Korea, Democratic People's Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations